Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01782053 · ClinicalTrials.gov registry record · Phase 3
Communicating Smoking Risks Through Graphic Warning Labels
A Phase 3 study of Lung Cancer and Heart Disease, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
- 2
- Study locations
NCT01782053: Completed Phase 3 study of Lung Cancer and Heart Disease, sponsored by University of Pennsylvania.
NCT01782053 is a Phase 3 study of Lung Cancer and Heart Disease that has completed, run by University of Pennsylvania. The registered enrollment target is 245 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01782053, a Phase 3 study of Lung Cancer and Heart Disease, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
- 2
- Study locations
Study Summary
Smoking is the largest preventable health risk in the U.S. The Family Smoking Prevention and Tobacco Control Act of 2010 mandated the placement of larger pictorial warnings on cigarette packs as well as nine new statements of smoking risks. This trial tests the effectiveness of the warnings proposed by the Food and Drug Administration by providing cigarettes with the proposed labels to 320 smokers across two sites (Philadelphia, PA and Columbus, OH). In addition, the trial tests the effects of different warning label components.
Conditions Studied
Interventions
- BEHAVIORAL Control
- BEHAVIORAL Picture warning
Study Locations (2)
Ohio
- Lazenby Hall, Ohio State University - Columbus
Pennsylvania
- Annenberg Public Policy Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
What the finished NCT01782053 record still lists
NCT01782053 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT01782053 reports a single indexed study location in Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01782053 about?
NCT01782053 is a clinical study titled "Communicating Smoking Risks Through Graphic Warning Labels". Smoking is the largest preventable health risk in the U.S. The Family Smoking Prevention and Tobacco Control Act of 2010 mandated the placement of larger pictorial warnings on cigarette packs as well as nine new statements of smoking risks. This trial tests the effectiveness of the warnings proposed...
What is the current status of trial NCT01782053?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2013-01. Estimated completion is 2014-04.
What conditions does trial NCT01782053 study?
This clinical trial studies the following conditions: Lung Cancer, Heart Disease.
What interventions are being tested in trial NCT01782053?
The interventions under investigation include: Control (BEHAVIORAL), Picture warning (BEHAVIORAL).
Who is sponsoring clinical trial NCT01782053?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01782053 being conducted?
This trial has 2 study locations across Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01782053's enrollment target sits among peer trials
245 115th of 409 higher than 295 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia